RecruitingInterventionalPhase 1Updated Oct 30, 2025
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With... | NCT00915525 | Trialant
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
ClinicalTrials.gov ID
NCT00915525
Lead Sponsor
AllerganINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Enrollment
829Actual
Last Update Posted
Apr 30, 2019Actual
Start Date
Feb 1, 2010Actual
Primary Completion Date
Aug 5, 2014Actual
Completion Date
Aug 5, 2014Actual
Brief Summary
The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.
Overactive Bladder
Urinary Incontinence
botulinum toxin Type A
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Participation in preceding study 191622-095 (NCT00910845) or 191622-520 (NCT00910520)
Exclusion Criteria:
Females who are pregnant, nursing or planning a pregnancy
Patient has any condition or situation which, in the Investigators opinion, would put the patient at risk from continuing treatment with botulinum toxin Type A